Avelumab
AssetAlso called MSB-0010682, MSB0010718C, Bavencio
Blocks PD-L1 to restore immune responses against tumor cells.
- Stage
- Approved
- Modality
- Antibody
- Target
- CD274
- 10
- Indications
- 259
- Trials
- 1
- Developer
Approved by the FDA on Mar 23, 2017 (BLA761049). 3 approvals stand. FDA
Indications
10Advanced Renal Cell Carcinoma
Approved, FDA
Locally advanced or metastatic urothelial carcinoma
Approved, FDA
Metastatic Merkel Cell Carcinoma
Approved, FDA
7 more
In the full profile
- Target and mechanism2
- Owner and partners2
- Trials259
- Evidence for its targets3
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.